Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9671821 | 0.90 | ADORA2A (0.51) | ADORA2AADORA2BADORA1ADORA3SLC28A2 | |
| SCHEMBL3520439 | 0.90 | ADORA2A (0.49) | ADORA2AADORA2BADORA1SLC28A2 | |
| SCHEMBL9673734 | 0.90 | ADORA2A (0.51) | ADORA2AADORA2BADORA1ADORA3 | |
| Bromide SCHEMBL9671949 | 0.89 | ADORA2A (0.50) | ADORA2AADORA2BADORA1ADORA3SLC28A2 | |
| SCHEMBL9671759 | 0.89 | ADORA2A (0.51) | ADORA2AADORA2BADORA1ADORA3SLC28A2 | |
| SCHEMBL965396 | 0.88 | ADORA2A (0.52) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL9671653 | 0.88 | ADORA2A (0.49) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL9672036 | 0.88 | NNMT (0.45) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL9671648 | 0.87 | ADORA2A (0.48) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL9671646 | 0.87 | SLC29A1 (0.52) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5102873-A | Viricides | SOUTHERN RESEARCH INSTITUTE (US) | 1992-04-07 | — | — | US | claimed |
| US-20150094327-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2015-04-02 | — | — | US | disclosed |
| EP-1868628-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF POXVIRUS INFECTIONS | CHIMERIX INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8642577-B2 | Compounds, compositions and methods for the treatment of poxvirus infections | CHIMERIX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | 2007-01-04 | — | — | US | disclosed |
| US-5102873-A | Viricides | SOUTHERN RESEARCH INSTITUTE (US) | 1992-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | IFNG, POLI, STING1 | ADORA2A 2217/4885ADORA2B 3315/4885ADORA1 3299/4885 |
| US-20150094327-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES | FEN1, RCE1, APEX1 | ADORA2A 1691/4885ADORA2B 2690/4885ADORA1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.